Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785842 | PMC |
| http://dx.doi.org/10.34067/KID.0001432021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacotherapy for Autoimmune Pulmonary Alveolar Proteinosis.
Drugs
August 2025
Service de Pneumologie, Centre de Référence Constitutif pour les Maladies Rares Pulmonaires, CHU de Rennes, IRSET UMR 1085, Université de Rennes, 2 rue Henri Le Guilloux, 35033, Rennes, France.
Pulmonary alveolar proteinosis is suspected when a "crazy paving" pattern is observed on a chest CT scan. This diagnosis is confirmed by the presence of eosinophilic extracellular material that shows positive staining with Periodic Acid Schiff on bronchoalveolar lavage samples. The autoimmune form of pulmonary alveolar proteinosis is confirmed by detecting anti-granulocyte-macrophage colony-stimulating factor antibodies in the patient's serum.
View Article and Find Full Text PDFSodium 2-Mercaptoethanesulfonate (MESNA), Ifosfamide, Mitoxantrone, and Etoposide (MINE) in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Is the Old Regimen Still Gold?
Cureus
July 2025
Department of Hematology and Bone Marrow Transplantation, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, PRT.
Introduction: For decades, the rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone (R-CHOP) regimen has been the standard treatment for aggressive B-cell non-Hodgkin lymphoma (NHL), such as diffuse large B-cell lymphoma (DLBCL). However, patients with relapsed or refractory (R/R) disease continue to face a poor prognosis. Those eligible for autologous hematopoietic stem cell transplantation (ASCT) are usually rescued with a platinum-containing regimen.
View Article and Find Full Text PDFHHV8-related diseases in solid organ transplantation: a case series and systematic literature review.
Clin Microbiol Infect
July 2025
Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy; Infectious Diseases Unit, Department of Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy. Electronic address:
Background: The true burden of HHV-8 in solid organ transplant (SOT) setting remains difficult to quantify and there are several uncertainties about the best prevention and management of HHV-8 related complications.
Objectives: To describe epidemiology and impact on outcome of HHV-8 related diseases in patients undergoing SOT, we reviewed all episodes diagnosed at our hospital over 8-year period and performed a narrative systematic literature review.
Sources: A search on PubMed, Scopus and Cochrane Library, according to Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines, was done.
Targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies.
Cochrane Database Syst Rev
August 2025
Department of Rheumatology, King's College Hospital, London, UK.
Background: Idiopathic inflammatory myopathies (IIM) are autoimmune-mediated inflammatory disorders of skeletal muscles with non-muscle involvement in some people. Treatment of IIM represents an area of unmet need; a previous Cochrane review (2012) found little or no evidence to guide treatment. Since then, potentially promising treatments targeting B and T cells and complement inhibitors have been investigated.
View Article and Find Full Text PDFCase Report: Subcutaneous ofatumumab for patients with immunosuppressant-dependent or ineffective primary membranous nephropathy.
Front Immunol
July 2025
Department of Nephrology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
CD20 monoclonal antibodies (mAbs), particularly rituximab, have become a preferred treatment for many patients with phospholipase A2 receptor (PLA2R)-related membranous nephropathy (MN). However, some patients either fail to respond to rituximab or experience adverse reactions, indicating that newer-generation CD20 mAbs may offer a more effective alternative. Recently, subcutaneous ofatumumab has been utilized in the treatment of relapsing multiple sclerosis (RMS).
View Article and Find Full Text PDF